Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease

Abstract

Although multiple antihypertensive agents are required to control blood pressure (BP) in chronic renal disease, it remains undetermined whether the combination therapy with angiotensin receptor blockers (ARB) plus calcium antagonists or angiotensin-converting enzyme inhibitors (ACEI) confers more preferable action on renal disease than the ARB monotherapy. In the present study, we compared the effect of the combination therapy with ARB plus calcium antagonists/ACEI on proteinuria with that of the ARB monotherapy in chronic nondiabetic renal disease. At 1 month of the drug treatment, the candesartan monotherapy (n=19) reduced BP from 154±3/93±2 to 146±3/88±2 mmHg (P<0.05), and a similar magnitude of BP reductions was observed with the combination therapy with candesartan plus ACEI/amlodipine (from 153±2/95±2 to 144±2/88±2 mmHg, P<0.05, n=39). The depressor action of these therapies was sustained throughout the 12-month treatment. In contrast, the reduction in proteinuria was greater with the combination therapy (−52±3% at 12 months, n=39) than with the candesartan monotherapy (−25±3%, n=19), although the baseline values of proteinuria were nearly the same in the candesartan monotherapy group (1.74±0.22 g/day) and the combination therapy group (2.10±0.19 g/day, P>0.2). Of note, the proteinuria-sparing effect did not differ between the candesartan+ACEI group and the candesartan+amlodipine group. In conclusion, the present study suggests more beneficial action of the combination therapy with ARB plus ACEI/amlodipine than the ARB monotherapy in nondiabetic renal disease. Since the reduction in BP was achieved to the same level, the distinct proteinuria-sparing action of these therapies is attributed to BP-independent mechanisms, which should vary depending on the agents used.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Shulman NB et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension 1989; 13(5 Suppl): I80–I93.

    Article  CAS  Google Scholar 

  2. Eddy AA . Interstitial nephritis induced by protein-overload proteinuria. Am J Pathol 1989; 135: 719–733.

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Pedrini MT et al. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal disease: a meta-analysis. Ann Intern Med 1996; 124: 627–632.

    Article  CAS  Google Scholar 

  4. Klahr S et al. The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease. N Engl J Med 1994; 330: 877–884.

    Article  CAS  Google Scholar 

  5. Peterson JC et al. Blood pressure control, proteinuria, and the progression of renal disease. Ann Intern Med 1995; 123: 754–762.

    Article  CAS  Google Scholar 

  6. Imanishi M et al. Mechanism of decreased albuminuria caused by angiotensin converting enzyme inhibitor in early diabetic nephropathy. Kidney Int Suppl 1997; 63: S198–S200.

    CAS  PubMed  Google Scholar 

  7. Raij L, Shultz PJ, Tolins JP . Possible mechanism for the renoprotective effect of angiotensin converting enzyme inhibitors. J Hypertens Suppl 1989; 7: S33–S36.

    Article  CAS  Google Scholar 

  8. Klag MJ et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334: 13–18.

    Article  CAS  Google Scholar 

  9. Bakris GL et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000; 36: 646–661.

    Article  CAS  Google Scholar 

  10. Russo D et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 2001; 38: 18–25.

    Article  CAS  Google Scholar 

  11. Nakao N et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomized controlled trial. Lancet 2003; 361: 117–124.

    Article  CAS  Google Scholar 

  12. Frohlich ED et al. Recommendations for human blood pressure determination by sphygmomanometers. Hypertension 1988; 11: 210A–216A.

    Google Scholar 

  13. Matsuda H, Hayashi K, Saruta T . Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease. J Hum Hypertens 2003; 17: 271–276.

    Article  CAS  Google Scholar 

  14. Matsuda H et al. Zonal heterogeneity in action of angiotensin-converting enzyme inhibitor on renal microcirculation: role of intrarenal bradykinin. J Am Soc Nephrol 1999; 10: 2272–2282.

    CAS  PubMed  Google Scholar 

  15. Endo Y et al. Function of angiotensin II type 2 receptor in the postglomerular efferent arteriole. Kidney Int Suppl 1997; 63: S205–S207.

    CAS  PubMed  Google Scholar 

  16. Herlitz H et al. The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros Study. Nephrol Dial Transplant 2001; 16: 2158–2165.

    Article  CAS  Google Scholar 

  17. Hayashi K et al. Disparate effects of calcium antagonist on renal microcirculation. Hypertens Res 1996; 19: 31–36.

    Article  CAS  Google Scholar 

  18. Jinno T et al. Calcium channel blocker azelnidipine enhances vascular protective effect of AT1 receptor blocker olmesartan. Hypertension 2004; 43: 263–269.

    Article  CAS  Google Scholar 

  19. Mogensen CE et al. Randomized controlled trial of dual blockade of renin–angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Br Med J 2000; 321: 1440–1444.

    Article  CAS  Google Scholar 

  20. Kuriyama S et al. Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy. Hypertens Res 2002; 25: 849–855.

    Article  CAS  Google Scholar 

  21. Staessen J et al. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 1981; 91: 457–465.

    Article  CAS  Google Scholar 

  22. Rocha R, Chander PN, Zuckerman A, Stier Jr CT . Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 1999; 33(1 Part 2): 232–237.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to K Hayashi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Homma, K., Hayashi, K., Kanda, T. et al. Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease. J Hum Hypertens 18, 879–884 (2004). https://doi.org/10.1038/sj.jhh.1001761

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jhh.1001761

Keywords

This article is cited by

Search

Quick links